ATE420210T1 - Diagnose des brustkrebsrisikos - Google Patents

Diagnose des brustkrebsrisikos

Info

Publication number
ATE420210T1
ATE420210T1 AT04768320T AT04768320T ATE420210T1 AT E420210 T1 ATE420210 T1 AT E420210T1 AT 04768320 T AT04768320 T AT 04768320T AT 04768320 T AT04768320 T AT 04768320T AT E420210 T1 ATE420210 T1 AT E420210T1
Authority
AT
Austria
Prior art keywords
breast cancer
diagnosis
cancer risk
risk
cancer
Prior art date
Application number
AT04768320T
Other languages
English (en)
Inventor
Martin Andrew Crockard
Janice Roberta Bailie
John Victor Lamont
Stephen Peter Fitzgerald
Original Assignee
Randox Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Randox Lab Ltd filed Critical Randox Lab Ltd
Application granted granted Critical
Publication of ATE420210T1 publication Critical patent/ATE420210T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Thermal Transfer Or Thermal Recording In General (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04768320T 2003-09-03 2004-09-02 Diagnose des brustkrebsrisikos ATE420210T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0320648.9A GB0320648D0 (en) 2003-09-03 2003-09-03 Molecular marker

Publications (1)

Publication Number Publication Date
ATE420210T1 true ATE420210T1 (de) 2009-01-15

Family

ID=28686847

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768320T ATE420210T1 (de) 2003-09-03 2004-09-02 Diagnose des brustkrebsrisikos

Country Status (9)

Country Link
US (1) US20090311671A1 (de)
EP (1) EP1660676B1 (de)
JP (1) JP2007503826A (de)
CN (1) CN1846001A (de)
AT (1) ATE420210T1 (de)
DE (1) DE602004018940D1 (de)
ES (1) ES2319533T3 (de)
GB (1) GB0320648D0 (de)
WO (1) WO2005024060A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606954D0 (en) * 2006-04-06 2006-05-17 Randox Lab Ltd Method
KR102071491B1 (ko) * 2017-11-10 2020-01-30 주식회사 디시젠 차세대 염기서열분석을 이용한 기계학습 기반 유방암 예후 예측 방법 및 예측 시스템

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044859A1 (en) * 1996-08-19 2003-03-06 Henslee Jerry G. Reagents and methods useful for detecting diseases of the breast
US6012053A (en) * 1997-06-23 2000-01-04 Lycos, Inc. Computer system with user-controlled relevance ranking of search results
JP3422776B2 (ja) * 1998-08-04 2003-06-30 ダイアデクスアス・インコーポレーテッド 乳癌を診断、監視、病期決定、造影及び治療する新規な方法
US7065494B1 (en) * 1999-06-25 2006-06-20 Nicholas D. Evans Electronic customer service and rating system and method
US6936424B1 (en) * 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
EP1267934A4 (de) * 1999-11-23 2004-03-17 Diadexus Inc Neues verfahren zur diagnose, überwachung, statusbestimmung, bildmässiger darstellung und behandlung von brustkrebs
US20020132237A1 (en) * 2000-05-26 2002-09-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
GB0026353D0 (en) * 2000-10-27 2000-12-13 Canon Kk Apparatus and a method for facilitating searching
CN1526025A (zh) * 2001-05-16 2004-09-01 ��˹��ŵ�� 作为预后和治疗靶标的乳腺癌中表达的基因
DK1410011T3 (da) * 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
US20040043950A1 (en) * 2002-01-03 2004-03-04 Board Of Regents, The University Of Texas System WT1 antisense oligos for the inhibition of breast cancer

Also Published As

Publication number Publication date
WO2005024060A1 (en) 2005-03-17
EP1660676B1 (de) 2009-01-07
CN1846001A (zh) 2006-10-11
US20090311671A1 (en) 2009-12-17
ES2319533T3 (es) 2009-05-08
JP2007503826A (ja) 2007-03-01
GB0320648D0 (en) 2003-10-01
DE602004018940D1 (de) 2009-02-26
EP1660676A1 (de) 2006-05-31

Similar Documents

Publication Publication Date Title
EP1556405A4 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
AU2002327308A1 (en) Methods for evaluating pathologic conditions using extracellular rna
DE60126593D1 (de) Diagnose von mit apoptose assoziierten erkrankungen mittels ermittlung des methylierungszustandes von apoptose-assozierten genen
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2004069174A3 (en) Monitoring and treatment of amyotrophic lateral sclerosis
DE60028544D1 (de) Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs
Ali et al. Molecular characterization of echinococcus species in Khyber pakhtunkhwa, pakistan
EP1565582A4 (de) Verfahren zur identifizierung des brustkrebsrisikos und behandlungen davon
DE602006015966D1 (de) Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
CN101045944B (zh) 检测六种腹泻致病菌的基因芯片、制备方法及试剂盒
EP1556493A4 (de) Neue vollständige genomische dna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
ATE523788T1 (de) ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN
ATE420210T1 (de) Diagnose des brustkrebsrisikos
ATE545708T1 (de) Krebsantigen mage-a9 und verwendungen davon
ATE431556T1 (de) Bestimmung von kurzkettiger srl- alkoholdehydrogenase (dhrs4) als biomarker für entzündungen und infektionen
BR0009573A (pt) Composições e métodos para o tratamento e diagnose do câncer de mama
ATE498020T1 (de) 5t4 rna in plasma und serum als marker für neoplastische erkrankungen
FI990380A7 (fi) Diagnostinen ja seulontamenetelmä
Lim et al. Prevalence of mupirocin resistance in methicillin-resistant Staphylococcus aureus strains isolated from a Malaysian hospital
GB0227274D0 (en) Probes
DE50214523D1 (de) Nukleotidträger zur diagnose und therapie oraler erkrankungen
MX2024005607A (es) Sustrato enzimatico fret y sus usos en el cancer de pulmon.
DE60035857D1 (de) Nukleinsäure- und aminosäuresequenzen von durch hämoglobin induzierbaren genen aus candida albicans und die verwendung dieser sequenzen in reagenzien zur diagnose von disseminierten candida albicans infektionen
AU2002323945B2 (en) Method of evaluating degree of canceration of mammal-origin specimen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties